4.7 Review

Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

期刊

AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 108, 期 8, 页码 1268-1276

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2013.138

关键词

-

资金

  1. MSD
  2. Merck
  3. Abbott

向作者/读者索取更多资源

OBJECTIVES: Several anti-tumor necrosis factor-alpha (TNF alpha) antibodies have demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). These drugs carry the theoretical risk of opportunistic infection, but no systematic review and meta-analysis has examined this issue specifically. METHODS: MEDLINE, EMBASE, and the Cochrane central register of controlled trials were searched (through to November 2012). Randomized controlled trials (RCTs) recruiting adults with active or quiescent CD or UC comparing anti-TNF alpha therapy with placebo were eligible. Dichotomous data were pooled to obtain a relative risk (RR) of opportunistic infection, with a 95 % confidence interval (CI). The number needed to harm (NNH) was estimated from the reciprocal of the risk difference from the meta-analysis. RESULTS: The search strategy identified 20,563 citations, 21 of which were eligible, reporting 22 separate RCTs with between 2 and 56 weeks of follow-up. In total, there were 39 (0.9 %) opportunistic infections among 4,135 patients allocated to anti-TNF alpha therapy, compared with 9 (0.3 %) among 2,919 assigned to placebo. Among patients receiving active therapy these included eight cases of Mycobacterium tuberculosis, eight cases of herpes simplex infection, six cases of oral or esophageal candidiasis, six cases of herpes zoster infection, two cases of varicella-zoster virus infection, two cases of cytomegalovirus or Epstein-Barr virus infection, and one case of Nocardia infection. The RR of developing an opportunistic infection was significantly higher with anti-TNF alpha therapy (2.05; 95 % CI 1.10-3.85, NNH = 500; 95 % CI 200-1,567). The RR of tuberculosis infection was 2.52 (95 % CI 0.62-10.21). CONCLUSIONS: Anti-TNF therapy doubles the risk of opportunistic infections in inflammatory bowel disease patients. This underlines the importance of adherence to guidelines for their prevention and management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据